News
ESMO Breast Cancer Congress 2026: Editor highlights
1+ day, 14+ hour ago (822+ words) Oncology Central is part of Taylor & Francis Group. The 2026 edition of the ESMO Breast Cancer Congress convened leading oncologists, researchers and healthcare professionals from around the world to explore key breakthroughs in breast cancer treatment and care. Held over 3 days,…...
Could GLP-1 receptor agonists improve breast cancer outcomes for patients with obesity or type 2 diabetes?
2+ day, 14+ hour ago (401+ words) Oncology Central is part of Taylor & Francis Group. Original story from the Virginia Commonwealth University Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists'drugs commonly used to treat obesity and…...
Highlights of the San Antonio Breast Cancer Symposium 2025
4+ day, 13+ hour ago (107+ words) Oncology Central Oncology Central is part of Taylor & Francis Group. Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick…...
ESMO Breast Cancer 2026: Could retrospective genetic testing improve care for cancer survivors?
1+ week, 1+ day ago (507+ words) Oncology Central is part of Taylor & Francis Group. Original story from ESMO Breast Cancer 2026 A national study has examined how genetic testing could better inform follow-up care for cancer survivors. Hundreds of thousands of people diagnosed with cancer are still…...
Could ct DNA aid treatment de-escalation for older ER-positive breast cancer patients?
1+ mon, 1+ day ago (70+ words) Oncology Central Oncology Central is part of Taylor & Francis Group. Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick…...
DNA methylome test shows promise for multi-cancer detection
1+ mon, 6+ day ago (795+ words) Oncology Central is part of Taylor & Francis Group. Original story from UCLA UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting multiple cancers, various liver conditions and organ abnormalities simultaneously by…...
ESMO 2025 and new therapies in breast cancer: does society always benefit?
1+ mon, 1+ week ago (222+ words) Oncology Central Oncology Central is part of Taylor & Francis Group. Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick…...
Bili Seq detects bile duct cancer with twice the sensitivity of standard test
1+ mon, 2+ week ago (563+ words) Oncology Central is part of Taylor & Francis Group. Original story from UPMC When patients develop a narrowing or blockage in the bile ducts " the tubes connecting the liver, gallbladder and intestines " physicians must determine whether the cause is cancer or…...
ct DNA could aid surgical de-escalation in older ER+ breast cancer patients
1+ mon, 3+ week ago (479+ words) Oncology Central is part of Taylor & Francis Group. Original story from UPMC For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools…...
Our top picks for the 15th European Breast Cancer Conference (EBCC-15)
1+ mon, 4+ week ago (326+ words) Oncology Central is part of Taylor & Francis Group. The 15th European Breast Cancer Conference (EBCC-15) will unite international breast cancer experts in Barcelona, Spain from March 2527, 2026. This multidisciplinary event promises a rich scientific program from which we've handpicked sessions of interest…...